|
|
![]() | ![]() | ![]() | ![]() |
This excerpt taken from the SMG 10-K filed Dec 14, 2006. Research and
Development
As the Company views its commitment to innovation as a
competitive advantage, the Company continually invests in
research and development to improve existing or develop new
products, manufacturing processes and packaging and delivery
systems. Spending on research and development was
$35.1 million, $38.0 million and $34.4 million in
fiscal 2006, fiscal 2005, and fiscal 2004, including
Table of Contents
registrations of $8.2 million, $7.5 million and $6.8 million,
respectively. The Companys long-standing commitment to
innovation is evidenced by a portfolio of patents worldwide that
supports many of our fertilizers, grass seeds and application
devices. In addition to the benefits of our own research and
development, we benefit from the research and development
activities of our suppliers.
Our research and development worldwide headquarters is located
at the Dwight G. Scott Research Center in Marysville, Ohio. We
also have research and development facilities in the United
Kingdom, France, the Netherlands and Sydney, Australia, as well
as several research field stations located throughout the United
States.
The Companys biotechnology program is evidence of its
commitment to responsible research in search of more effective
and
easier-to-use
products that are preferred by consumers and are better for the
environment. By employing technology already proven in
agriculture, the Company is working to develop turf varieties
that could one day require less maintenance, less water and
fewer chemical inputs to resist insects, weeds and disease.
Before a product enhanced with biotechnology may be sold in the
United States, it must be deregulated by appropriate
governmental agencies. Deregulation involves compliance with the
rules and regulations of, and cooperation with, the United
States Department of Agriculture (the USDA), Animal
and Plant Health Inspection Service, the United States
Environmental Protection Agency (the U.S. EPA)
and/or the
Food and Drug Administration (the FDA). As part of
the deregulation process for any product enhanced with
biotechnology, we are required to present evidence to the USDA
in the form of scientifically rigorous studies showing that the
product poses no additional toxicological or ecological risk
than products of the same species that have not been enhanced
with biotechnology. We are also required to satisfy other
agencies, such as the U.S. EPA and the FDA, as to their
appropriate areas of regulatory authority. This process
typically takes years to complete and also includes at least two
opportunities for public comment. Therefore, any enhanced
product for which we seek commercialization through submission
of a petition for deregulation will be subjected to rigorous and
thorough governmental regulatory review.
We submitted a petition for deregulation of a non-residential
turfgrass product enhanced with biotechnology to the USDA on
April 14, 2003. This turfgrass has been shown, through our
research trials, to provide simple, more flexible and better
weed control for golf courses in a manner we believe is more
environmentally friendly. The USDA has a variety of options in
adjudicating a petition to deregulate a
biotechnology-derived plant product. The USDA has decided to
employ the formal Environmental Impact Statement
(EIS) process to judge the acceptability of our
petition for deregulation. We welcome this process as the most
thorough evaluative step available to the USDA.
We believe there is a substantial market for turfgrass products
enhanced with biotechnology, and our product, if approved, can
capture a significant portion of this market. However, there can
be no assurance our petition for deregulation of this product
will be approved, or if approved and commercially introduced,
this product will generate any revenues or contribute to our
earnings.
|
| |||||||